Search
Now showing items 1-2 of 2
Lopinavir Plus Nucleoside Reverse-transcriptase Inhibitors, Lopinavir Plus Raltegravir, or Lopinavir Monotherapy for Second-line Treatment of HIV (EARNEST): 144-week Follow-up Results From a Randomised Controlled Trial
(Elsevier, 2018-01)
Background Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir ...
Feasibility and acceptability of integrating hepatitis B care into routine HIV services: a qualitative study among health care providers and patients in West Nile region, Uganda
(BMC Springer Nature, 2023-01-20)
Despite facing a dual burden of HBV and HIV, Africa lacks experience in ofering integrated care for HIV
and HBV. To contextualize individual and group-level feasibility and acceptability of an integrated HIV/HBV care ...